Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can genetic screening help prevent cancer in underserved communities?

NCT ID NCT03426878

Knowledge-focused Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at whether offering exome sequencing (a detailed genetic test) along with tailored genetic counseling helps people at high risk for hereditary cancer syndromes understand their risk and take action. Nearly 1,000 adults from diverse backgrounds in Colorado and Oregon participated. The goal was to see how well this approach works in real-world primary care settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exome sequencing and genetic counseling
What this could lead to
If successful, this could help tailor cancer risk assessment and genetic counseling for diverse populations, potentially leading to earlier detection and prevention.
What could go wrong
This is a completed observational study with a small sample size (967 participants) and focuses on feasibility and utility, not treatment outcomes. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

967 people

The number who actually took part.

Started

Aug 2018

Finished

Feb 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 49 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Kaiser Permanente Northwest or Denver Health patient * Screens as high risk for a hereditary cancer syndrome via the risk assessment tool algorithms OR have unknown family history on either their mother or father's side of the family (or both) * No known prior testing for familial mutations predisposing them to Lynch syndrome or hereditary breast and ovarian cancer * English or Spanish speaker Exclusion Criteria: * Participant self-reported prior testing for Lynch syndrome (LS) or Hereditary Breast and Ovarian Cancer (HBOC) syndrome or identified as having previous comprehensive testing via Kaiser Permanente data files * Not an English or Spanish speaker * Unable to provide informed consent * Don't want results placed in their medical record

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary cancer syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis hereditary breast ovarian cancer syndrome hereditary neoplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary cancer syndrome

Contacts and locations

Locations

  • Denver Health

    Denver, Colorado, 80204, United States

  • Kaiser Permanente Center for Health Research

    Portland, Oregon, 97227, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.